CA2304819A1 - Perforated microparticles and methods of use - Google Patents
Perforated microparticles and methods of use Download PDFInfo
- Publication number
- CA2304819A1 CA2304819A1 CA002304819A CA2304819A CA2304819A1 CA 2304819 A1 CA2304819 A1 CA 2304819A1 CA 002304819 A CA002304819 A CA 002304819A CA 2304819 A CA2304819 A CA 2304819A CA 2304819 A1 CA2304819 A1 CA 2304819A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- methods
- perforated microparticles
- microparticles
- perforated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Abstract
Engineered particles are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6033797P | 1997-09-29 | 1997-09-29 | |
US10693298A | 1998-06-29 | 1998-06-29 | |
US13384898A | 1998-08-14 | 1998-08-14 | |
US09/106,932 | 1998-08-14 | ||
US60/060,337 | 1998-08-14 | ||
US09/133,848 | 1998-08-14 | ||
PCT/US1998/020602 WO1999016419A1 (en) | 1997-09-29 | 1998-09-29 | Perforated microparticles and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2304819A1 true CA2304819A1 (en) | 1999-04-08 |
CA2304819C CA2304819C (en) | 2008-04-08 |
Family
ID=27369827
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002304975A Expired - Lifetime CA2304975C (en) | 1997-09-29 | 1998-09-29 | Stabilized preparations for use in metered dose inhalers |
CA002304819A Expired - Lifetime CA2304819C (en) | 1997-09-29 | 1998-09-29 | Perforated microparticles and methods of use |
CA002304820A Expired - Fee Related CA2304820C (en) | 1997-09-29 | 1998-09-29 | Stabilized bioactive preparations and methods of use |
CA002304973A Expired - Fee Related CA2304973C (en) | 1997-09-29 | 1998-09-29 | Stabilized preparations for use in nebulizers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002304975A Expired - Lifetime CA2304975C (en) | 1997-09-29 | 1998-09-29 | Stabilized preparations for use in metered dose inhalers |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002304820A Expired - Fee Related CA2304820C (en) | 1997-09-29 | 1998-09-29 | Stabilized bioactive preparations and methods of use |
CA002304973A Expired - Fee Related CA2304973C (en) | 1997-09-29 | 1998-09-29 | Stabilized preparations for use in nebulizers |
Country Status (28)
Country | Link |
---|---|
EP (4) | EP1019023B1 (en) |
JP (9) | JP2003525842A (en) |
KR (4) | KR100599634B1 (en) |
CN (1) | CN1169520C (en) |
AT (3) | ATE248583T1 (en) |
AU (4) | AU757153B2 (en) |
BG (1) | BG64816B1 (en) |
BR (1) | BR9812693A (en) |
CA (4) | CA2304975C (en) |
CZ (1) | CZ300758B6 (en) |
DE (2) | DE69814428T2 (en) |
DK (2) | DK1019021T4 (en) |
EA (2) | EA002562B1 (en) |
EE (1) | EE04628B1 (en) |
ES (3) | ES2205560T5 (en) |
HK (1) | HK1031680A1 (en) |
HR (1) | HRP20000175B1 (en) |
IL (2) | IL135126A0 (en) |
IS (1) | IS2154B (en) |
ME (1) | MEP4108A (en) |
NO (1) | NO340149B1 (en) |
NZ (1) | NZ503464A (en) |
PL (1) | PL195212B1 (en) |
PT (1) | PT1019022E (en) |
RS (1) | RS50182B (en) |
SK (1) | SK285068B6 (en) |
TR (1) | TR200000819T2 (en) |
WO (3) | WO1999016422A1 (en) |
Families Citing this family (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
ATE248583T1 (en) * | 1997-09-29 | 2003-09-15 | Nektar Therapeutics | STABILIZED PREPARATIONS USABLE IN DOSAGE INHALERS |
GB9727102D0 (en) * | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
CA2335940A1 (en) * | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
WO2000000215A1 (en) * | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
ES2250141T5 (en) * | 1999-05-27 | 2009-11-05 | Acusphere, Inc. | POROUS MATRICES OF DRUGS AND METHODS TO MANUFACTURE THEM. |
AU782916B2 (en) | 1999-06-09 | 2005-09-08 | Robert E. Sievers | Supercritical fluid-assisted nebulization and bubble drying |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
EP1210067A2 (en) * | 1999-08-25 | 2002-06-05 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
WO2001045731A1 (en) | 1999-12-21 | 2001-06-28 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
WO2001058697A2 (en) | 2000-02-08 | 2001-08-16 | 3M Innovative Properties Company | Ink fixing materials and methods of fixing ink |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
ATE304453T1 (en) | 2000-02-08 | 2005-09-15 | 3M Innovative Properties Co | IMPROVED METHODS FOR COLD IMAGE TRANSFER |
ES2525087T5 (en) * | 2000-05-10 | 2018-06-28 | Novartis Ag | Phospholipid-based powders for drug administration |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
AU2001254995A1 (en) * | 2000-05-15 | 2001-11-26 | Vectura Limited | Method of manufacturing particles |
NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
US7141236B2 (en) | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
DE10064219B9 (en) * | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Novel pharmaceutical composition containing fentanyl and / or its derivatives |
US20030072717A1 (en) | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
GB0106403D0 (en) * | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
GB0107106D0 (en) * | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
WO2002087542A1 (en) * | 2001-04-26 | 2002-11-07 | Inhale Therapeutic Systems, Inc. | Novel methods and compositions for delivering macromolecules to or via the respiratory tract |
US7905230B2 (en) | 2001-05-09 | 2011-03-15 | Novartis Ag | Metered dose inhaler with lockout |
CN1236831C (en) * | 2001-05-21 | 2006-01-18 | 茵捷特数码浮质有限公司 | Compositions for protein delivery via the pulmonary route |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
ATE415155T1 (en) | 2001-05-24 | 2008-12-15 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM, OR TRIAZOLAM BY INHALATION |
US6759029B2 (en) | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
JP2004531333A (en) | 2001-06-20 | 2004-10-14 | ネクター セラピューティクス | Powder aerosolization apparatus and method |
JP2005507881A (en) | 2001-09-17 | 2005-03-24 | グラクソ グループ リミテッド | Dry powder pharmaceutical formulation |
AU2002342241B2 (en) | 2001-11-01 | 2007-07-19 | Novartis Ag | Spray drying methods and compositions thereof |
WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
SI1458360T1 (en) | 2001-12-19 | 2011-08-31 | Novartis Ag | Pulmonary delivery of aminoglycosides |
WO2003057593A1 (en) | 2001-12-21 | 2003-07-17 | Nektar Therapeutics | Capsule package with moisture barrier |
WO2003077891A1 (en) * | 2002-03-18 | 2003-09-25 | Yamanouchi Pharmaceutical Co., Ltd. | Powdery medicinal compositions for inhalation and process for producing the same |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
US6941980B2 (en) | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
PE20040134A1 (en) | 2002-07-25 | 2004-03-06 | Pharmacia Corp | PRAMIPEXOL ONCE-A-DAY DOSAGE FORM |
CA2500065A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
WO2004054556A1 (en) * | 2002-12-13 | 2004-07-01 | Adagit | Pharmaceutical porous particles |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
EP1589947B2 (en) * | 2002-12-31 | 2019-01-30 | Novartis AG | Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
WO2004073729A1 (en) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | Compositions for nasal administration of drug |
AU2004216298B2 (en) * | 2003-02-28 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
KR100974482B1 (en) | 2003-03-27 | 2010-08-10 | 가부시키가이샤 바이오악티스 | Powder medicine applicator for nasal cavity |
CA2520265C (en) | 2003-04-09 | 2015-02-17 | Nektar Therapeutics | Aerosolization apparatus with capsule puncture alignment guide |
US8869794B1 (en) | 2003-04-09 | 2014-10-28 | Novartis Pharma Ag | Aerosolization apparatus with capsule puncturing member |
SI1610850T2 (en) | 2003-04-09 | 2020-11-30 | Novartis Ag | Aerosolization apparatus with air inlet shield |
WO2004104491A2 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Percussively ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
EP1635786A2 (en) | 2003-05-28 | 2006-03-22 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
US20050069591A1 (en) * | 2003-09-30 | 2005-03-31 | Howard Bernstein | Injectable, oral, or topical sustained release pharmaceutical formulations |
US7621299B2 (en) | 2003-10-03 | 2009-11-24 | Cabot Corporation | Method and apparatus for filling a vessel with particulate matter |
AU2004285595A1 (en) * | 2003-10-31 | 2005-05-12 | Point Biomedical Corporation | Reconstitutable microsphere compositions useful as ultrasonic contrast agents |
US7192919B2 (en) | 2004-01-07 | 2007-03-20 | Stelios Tzannis | Sustained release compositions for delivery of pharmaceutical proteins |
CA2562606A1 (en) * | 2004-04-13 | 2005-10-27 | Cambridge Biostability Limited | Liquids containing suspended glass particles |
ITMI20040795A1 (en) * | 2004-04-23 | 2004-07-23 | Eratech S R L | DRY SOLID PHARMACEUTICAL COMPOSITION ON ITS STABLE WATER PREPARATION AND SUSPENSION PROCESS OBTAINED BY ITSELF |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
CA2567785A1 (en) | 2004-06-21 | 2006-01-05 | Nektar Therapeutics | Composition comprising amphotericin b methods and systems |
US8673360B2 (en) | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
JP4757872B2 (en) | 2004-08-13 | 2011-08-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof |
CA2576386A1 (en) | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US8299025B2 (en) | 2005-02-03 | 2012-10-30 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8003127B2 (en) | 2005-03-23 | 2011-08-23 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
WO2006124446A2 (en) * | 2005-05-12 | 2006-11-23 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
MX2007014531A (en) | 2005-05-18 | 2008-04-29 | Nektar Therapeutics | Valves, devices, and methods for endobronchial therapy. |
PE20061444A1 (en) | 2005-05-19 | 2007-01-15 | Centocor Inc | ANTI-MCP-1 ANTIBODY, COMPOSITIONS, METHODS AND USES |
PT1896073E (en) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Anti-il-23 antibodies, compositions, methods and uses |
ITMI20051999A1 (en) | 2005-10-21 | 2007-04-22 | Eratech S R L | INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY |
JP5113328B2 (en) * | 2005-11-07 | 2013-01-09 | 田辺三菱製薬株式会社 | Emulsion, method for producing target substance particles using the same, and pharmaceutical product |
EP1968644B1 (en) | 2005-12-16 | 2012-06-27 | Nektar Therapeutics | Polymer conjugates of glp-1 |
MX2008008621A (en) | 2005-12-29 | 2008-11-27 | Centocor Inc | Human anti-il-23 antibodies, compositions, methods and uses. |
EP1976486A1 (en) * | 2006-01-27 | 2008-10-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
KR101106510B1 (en) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | Two-piece, internal-channel osmotic delivery system flow modulator |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
EP2116264B1 (en) | 2006-12-26 | 2017-09-27 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
WO2009023803A2 (en) * | 2007-08-15 | 2009-02-19 | Abbott Respiratory Llc | Modulated release formulation for the delivery of one or more medicaments |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
WO2009120619A2 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
PL220269B1 (en) | 2008-04-21 | 2015-09-30 | Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna | Composite carrier of powdered medicines, method of production the medicine carrier and equipment for production of particles of composite carrier |
KR101621986B1 (en) | 2008-05-15 | 2016-05-17 | 노파르티스 아게 | Pulmonary delivery of a fluoroquinolone |
US8680263B2 (en) | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
DK2356269T3 (en) | 2008-10-31 | 2016-08-15 | Janssen Biotech Inc | FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS |
MX2011004730A (en) * | 2008-11-04 | 2011-05-30 | Cipla Ltd | Pharmaceutical aerosol composition. |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP2221048A1 (en) | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
US8974828B2 (en) | 2009-03-18 | 2015-03-10 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
EP3184099A1 (en) | 2009-03-26 | 2017-06-28 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
KR20100123240A (en) * | 2009-05-15 | 2010-11-24 | 포항공과대학교 산학협력단 | Respiratory administering pharmaceutical agent for treating or preventing respiratory inflammatory diseases and method for treating or preventing the same diseases |
JP2012526726A (en) | 2009-05-15 | 2012-11-01 | 株式会社新日本科学 | Intranasal pharmaceutical composition with improved pharmacokinetics |
KR101976107B1 (en) * | 2009-05-29 | 2019-05-09 | 펄 테라퓨틱스 인코포레이티드 | Respiratory delivery of active agents |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
GB2472327B (en) | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
HUE035862T2 (en) | 2009-09-28 | 2018-05-28 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
WO2011069197A1 (en) * | 2009-12-08 | 2011-06-16 | The University Of Sydney | Inhalable formulations |
WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
US9642798B2 (en) | 2010-09-29 | 2017-05-09 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
US9433576B2 (en) | 2010-09-29 | 2016-09-06 | Pulmatrix, Inc. | Cationic dry powders |
US9492387B2 (en) | 2010-10-29 | 2016-11-15 | Western University Of Health Sciences | Ternary mixture formulations |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CA2827990A1 (en) * | 2011-02-25 | 2012-08-30 | The Johns Hopkins University | Chalcone derivatives as nrf2 activators |
GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
CN103687483A (en) * | 2011-05-17 | 2014-03-26 | 珍珠治疗公司 | Compositions, methods & systems for respiratory delivery of two or more active agents |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
EP2601941A1 (en) | 2011-12-06 | 2013-06-12 | Ludwig-Maximilians-Universität München | Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents |
WO2013153146A1 (en) | 2012-04-13 | 2013-10-17 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
ES2749096T3 (en) | 2012-10-25 | 2020-03-19 | Massachusetts Gen Hospital | Combination therapies for the treatment of Alzheimer's disease and related disorders |
SG11201507286QA (en) | 2013-03-15 | 2015-10-29 | Pearl Therapeutics Inc | Methods and systems for conditioning of particulate crystalline materials |
GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
CA2910766C (en) | 2013-04-30 | 2020-12-15 | Otitopic Inc. | Dry powder formulations and methods of use |
KR101543507B1 (en) * | 2013-05-15 | 2015-08-11 | 씨제이헬스케어 주식회사 | A continuous process for preparing microspheres and microspheres prepared thereby |
EP2999337A4 (en) * | 2013-05-23 | 2017-03-15 | Aztherapies, Inc | Methods for delivering cromolyn |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
WO2014207213A1 (en) | 2013-06-28 | 2014-12-31 | Medizinische Universität Innsbruck | Novel inhibitors of protein kinase c epsilon signaling |
CN110305095A (en) * | 2013-10-22 | 2019-10-08 | 综合医院公司 | Cromoglycic acid derivative and the correlation technique of imaging and treatment |
DK3104854T3 (en) | 2014-02-10 | 2020-05-04 | Respivant Sciences Gmbh | MAST-CELL STABILIZERS FOR HEALTH DISEASE TREATMENT |
CA2938994A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Inhalable formulations of sodium cromolyn with improved bioavailability |
PL3107548T3 (en) | 2014-02-20 | 2022-10-31 | Otitopic Inc. | Dry powder formulations for inhalation |
EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
CN116687887A (en) | 2014-07-31 | 2023-09-05 | 维克图拉公司 | Dry powder formulations for inhalation |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
JP6395216B2 (en) * | 2014-11-13 | 2018-09-26 | 国立大学法人大阪大学 | Method and apparatus for measuring ultrafine bubbles contained in liquid |
US10668015B2 (en) | 2015-01-20 | 2020-06-02 | Incarda Therapeutics, Inc. | Unit aerosol doses for anticoagulation |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016170102A1 (en) | 2015-04-22 | 2016-10-27 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
ES2866175T3 (en) | 2015-12-04 | 2021-10-19 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
AU2016367306B2 (en) | 2015-12-09 | 2021-04-22 | Medizinische Universität Wien | Monomaleimide-functionalized platinum compounds for cancer therapy |
AU2017207867A1 (en) | 2016-01-15 | 2018-08-09 | Universität Hamburg | Flavonoide-type compounds bearing an O-rhamnosyl residue |
EP3411030A4 (en) | 2016-02-01 | 2019-09-04 | InCarda Therapeutics, Inc. | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
US10702518B2 (en) | 2016-02-15 | 2020-07-07 | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH | TAF1 inhibitors for the therapy of cancer |
EP3436477A2 (en) | 2016-03-29 | 2019-02-06 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody |
ES2957548T3 (en) | 2016-04-15 | 2024-01-22 | Univ Oxford Innovation Ltd | Adenosine receptor modulators for the treatment of circadian rhythm disorders |
BR112018073511A2 (en) | 2016-05-16 | 2019-03-26 | Intarcia Therapeutics, Inc. | glucagon receptor selective polypeptides and methods of use |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
CA3026757A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
AU2017296237A1 (en) | 2016-07-15 | 2019-01-03 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use |
EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
AU2017321782B2 (en) | 2016-08-31 | 2022-03-10 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
AU2017328910B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
ES2892673T3 (en) | 2016-09-19 | 2022-02-04 | Mexichem Fluor Sa De Cv | Pharmaceutical composition comprising glycopyrrolate |
AU2017328908B2 (en) | 2016-09-19 | 2020-04-02 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
EP3909582B1 (en) | 2016-09-19 | 2023-05-24 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising indacaterol |
MA46366A (en) | 2016-09-30 | 2019-08-07 | Janssen Biotech Inc | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTIBODY AGAINST IL-23 |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | Cromolyn compositions for treatment of pulmonary fibrosis |
CN110225755A (en) | 2016-11-14 | 2019-09-10 | 分子医学研究中心责任有限公司 | The combination of BRD4 inhibitor and antifol is used for treating cancer |
EP3541422A4 (en) | 2016-11-16 | 2020-05-06 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-il-23 specific antibody |
CN110225762A (en) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent |
KR20200003199A (en) | 2017-05-10 | 2020-01-08 | 인카다 테라퓨틱스, 인크. | Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration |
CA3062567A1 (en) | 2017-05-22 | 2018-11-29 | Insmed Incorporated | Glycopeptide derivative compounds and uses thereof |
KR20210070232A (en) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | Powdered Formulation of Cromolin Sodium and Ibuprofen |
CN111727256A (en) | 2017-09-08 | 2020-09-29 | 波赛达治疗公司 | Compositions and methods for Chimeric Ligand Receptor (CLR) -mediated conditional gene expression |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
WO2019110139A1 (en) | 2017-12-05 | 2019-06-13 | Eth Zurich | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors |
KR20200116917A (en) | 2017-12-20 | 2020-10-13 | 포세이다 테라퓨틱스, 인크. | VCAR composition and method of use |
AU2019232624A1 (en) | 2018-03-05 | 2020-09-10 | Janssen Biotech, Inc. | Methods of treating Crohn's disease with anti-IL23 specific antibody |
MX2020009309A (en) | 2018-03-07 | 2021-01-08 | Poseida Therapeutics Inc | Cartyrin compositions and methods for use. |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
US20210022978A1 (en) | 2018-04-06 | 2021-01-28 | Zilentin AG | Bumetanide derivatives for the therapy of hyperhidrosis |
US20210163406A1 (en) | 2018-04-06 | 2021-06-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs |
MA52590A (en) | 2018-05-11 | 2021-03-17 | Janssen Biotech Inc | METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES |
US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
CN113038944A (en) | 2018-07-02 | 2021-06-25 | 通用医疗公司 | Powdered preparation of cromolyn sodium and alpha-lactose |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
EP3883606B9 (en) | 2018-09-24 | 2023-10-04 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
CN113395979A (en) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies |
WO2020127200A1 (en) | 2018-12-17 | 2020-06-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
EP3897722A4 (en) | 2018-12-18 | 2022-09-14 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
MX2021008149A (en) | 2019-01-03 | 2021-11-12 | Aqua Yield Operations LLC | Pamam dendrimers for fertilizer delivery. |
US20200291107A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions |
CN113853385A (en) | 2019-03-18 | 2021-12-28 | 詹森生物科技公司 | Methods of treating psoriasis in pediatric subjects with anti-IL 12/IL23 antibodies |
US11932585B2 (en) | 2019-04-12 | 2024-03-19 | Aqua Yield Operations LLC | Blended nanoparticle fertilizer delivery |
CN110051868A (en) * | 2019-04-15 | 2019-07-26 | 宝盈联华(厦门)生物科技有限公司 | A kind of cabinet sterilizer with silicon-carbon rock, Lei mountain flour |
JP7404671B2 (en) * | 2019-06-25 | 2023-12-26 | 株式会社リコー | Porous fine particles and their manufacturing method, and pharmaceutical compositions |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
WO2021064141A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
KR20220079597A (en) | 2019-10-02 | 2022-06-13 | 톨레모 테라퓨틱스 아게 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
WO2021074418A1 (en) | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof |
AU2020366135A1 (en) | 2019-10-16 | 2022-06-02 | Proxygen Gmbh | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof |
CA3174777A1 (en) | 2020-04-14 | 2021-10-21 | Eric M. Ostertag | Compositions and methods for use in the treatment of cancer |
US20230158125A1 (en) | 2020-04-20 | 2023-05-25 | Sorrento Therapeutics, Inc. | Pulmonary Administration of ACE2 Polypeptides |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
CA3184062A1 (en) | 2020-06-25 | 2021-12-30 | Stefanie Fluckiger-Mangual | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
EP3939578A1 (en) | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
CN111700883B (en) * | 2020-07-23 | 2021-04-06 | 深圳大佛药业股份有限公司 | Salbutamol sulfate sustained-release inhalation preparation and production process thereof |
EP4208154A1 (en) | 2020-09-04 | 2023-07-12 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
EP3964497A1 (en) | 2020-09-04 | 2022-03-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain |
CA3194868A1 (en) | 2020-10-16 | 2022-04-21 | Georg Winter | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
CN112495316B (en) * | 2020-10-20 | 2021-11-19 | 大连理工大学 | Method for preparing micro-nano gel microspheres based on metastable emulsion |
TW202237102A (en) * | 2020-12-11 | 2022-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Pharmaceutical compositions for pulmonary delivery |
WO2022189662A1 (en) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
CA3213278A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
KR20230156387A (en) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | Safe and effective method of treating psoriatic arthritis by anti-IL23 specific antibody |
AU2022253869A1 (en) | 2021-04-07 | 2023-10-05 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-il12/il23 antibody compositions |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023203174A1 (en) | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1410588A (en) † | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
JPS5134879A (en) * | 1974-09-19 | 1976-03-24 | Eisai Co Ltd | Bishochukuryushinoseizoho |
US4147766A (en) † | 1976-06-09 | 1979-04-03 | Armour Pharmaceutical Company | Macrospherical particles of anti-perspirants |
DE3268533D1 (en) † | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
EP0391893B1 (en) * | 1983-11-14 | 1993-08-25 | The University of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
GB8502892D0 (en) * | 1985-02-05 | 1985-03-06 | Sterwin Ag | Aerosol composition |
ATE78158T1 (en) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES. |
US4950477A (en) † | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
JPH0739339B2 (en) * | 1989-05-01 | 1995-05-01 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Method for producing small particles of bioactive molecule |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
EP0527940A1 (en) † | 1990-05-08 | 1993-02-24 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
US5126123A (en) † | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5230884A (en) † | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5304125A (en) † | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
ES2097783T3 (en) * | 1991-01-15 | 1997-04-16 | Hemosphere Inc | PROTEIN NANOMATRICES AND PRODUCTION PROCEDURE. |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5182097A (en) † | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
WO1992016192A1 (en) † | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
SE9101090D0 (en) * | 1991-04-11 | 1991-04-11 | Astra Ab | PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES |
JPH05500229A (en) * | 1991-04-12 | 1993-01-21 | 東レ株式会社 | Aerosol formulation of solid polypeptide microparticles and its manufacturing method |
US5474759A (en) * | 1991-06-10 | 1995-12-12 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
ATE150296T1 (en) * | 1991-12-18 | 1997-04-15 | Minnesota Mining & Mfg | AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS |
US5376359A (en) † | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
DE4323636A1 (en) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation |
EP0711179B2 (en) * | 1993-07-30 | 2010-09-01 | IMCOR Pharmaceutical Co. | Stabilized microbubble compositions for ultrasound |
US5798091A (en) † | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
EP0655237A1 (en) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medicinal aerosol formulation |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
MX9702357A (en) * | 1994-09-29 | 1997-06-28 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles. |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
US6932962B1 (en) * | 1994-12-22 | 2005-08-23 | Astrazeneca Ab | Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides |
CA2218074C (en) * | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
CN1083280C (en) † | 1995-06-07 | 2002-04-24 | ImaRx药物公司 | Novel targeted compositions for diagnostic and therapeutic use |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
JP3884484B2 (en) † | 1997-01-16 | 2007-02-21 | マサチューセッツ インスティチュート オブ テクノロジー | Preparation of particles for inhalation |
ATE248583T1 (en) * | 1997-09-29 | 2003-09-15 | Nektar Therapeutics | STABILIZED PREPARATIONS USABLE IN DOSAGE INHALERS |
-
1998
- 1998-09-29 AT AT98950826T patent/ATE248583T1/en not_active IP Right Cessation
- 1998-09-29 DE DE69814428T patent/DE69814428T2/en not_active Expired - Lifetime
- 1998-09-29 KR KR1020007003368A patent/KR100599634B1/en not_active IP Right Cessation
- 1998-09-29 CA CA002304975A patent/CA2304975C/en not_active Expired - Lifetime
- 1998-09-29 CA CA002304819A patent/CA2304819C/en not_active Expired - Lifetime
- 1998-09-29 EP EP98954933A patent/EP1019023B1/en not_active Expired - Lifetime
- 1998-09-29 JP JP2000513560A patent/JP2003525842A/en not_active Withdrawn
- 1998-09-29 BR BR9812693-8A patent/BR9812693A/en not_active Application Discontinuation
- 1998-09-29 RS YUP-183/00A patent/RS50182B/en unknown
- 1998-09-29 AT AT98954933T patent/ATE239447T1/en not_active IP Right Cessation
- 1998-09-29 WO PCT/US1998/020615 patent/WO1999016422A1/en active IP Right Grant
- 1998-09-29 NZ NZ503464A patent/NZ503464A/en not_active IP Right Cessation
- 1998-09-29 DE DE69813853T patent/DE69813853T3/en not_active Expired - Lifetime
- 1998-09-29 CZ CZ20001115A patent/CZ300758B6/en not_active IP Right Cessation
- 1998-09-29 WO PCT/US1998/020602 patent/WO1999016419A1/en active Application Filing
- 1998-09-29 JP JP2000513559A patent/JP4526702B2/en not_active Expired - Fee Related
- 1998-09-29 AU AU96772/98A patent/AU757153B2/en not_active Expired
- 1998-09-29 EA EA200000375A patent/EA002562B1/en not_active IP Right Cessation
- 1998-09-29 CN CNB98809603XA patent/CN1169520C/en not_active Expired - Lifetime
- 1998-09-29 TR TR2000/00819T patent/TR200000819T2/en unknown
- 1998-09-29 EA EA200200036A patent/EA003665B1/en not_active IP Right Cessation
- 1998-09-29 CA CA002304820A patent/CA2304820C/en not_active Expired - Fee Related
- 1998-09-29 AU AU11857/99A patent/AU750567B2/en not_active Ceased
- 1998-09-29 JP JP2000513558A patent/JP2001517692A/en active Pending
- 1998-09-29 PT PT98953220T patent/PT1019022E/en unknown
- 1998-09-29 AU AU96770/98A patent/AU756693B2/en not_active Ceased
- 1998-09-29 ES ES98950826T patent/ES2205560T5/en not_active Expired - Lifetime
- 1998-09-29 ES ES98954933T patent/ES2195415T3/en not_active Expired - Lifetime
- 1998-09-29 DK DK98950826.2T patent/DK1019021T4/en active
- 1998-09-29 PL PL98339732A patent/PL195212B1/en unknown
- 1998-09-29 KR KR1020007003401A patent/KR100575070B1/en not_active IP Right Cessation
- 1998-09-29 EE EEP200000194A patent/EE04628B1/en unknown
- 1998-09-29 JP JP2000513557A patent/JP5372306B2/en not_active Expired - Lifetime
- 1998-09-29 SK SK449-2000A patent/SK285068B6/en not_active IP Right Cessation
- 1998-09-29 AU AU10644/99A patent/AU757337C/en not_active Expired
- 1998-09-29 IL IL13512698A patent/IL135126A0/en active IP Right Grant
- 1998-09-29 KR KR1020007003367A patent/KR100589926B1/en not_active IP Right Cessation
- 1998-09-29 KR KR1020007003416A patent/KR100572171B1/en not_active IP Right Cessation
- 1998-09-29 EP EP98953220A patent/EP1019022B2/en not_active Expired - Lifetime
- 1998-09-29 AT AT98953220T patent/ATE238035T1/en active
- 1998-09-29 DK DK98953220.5T patent/DK1019022T4/en active
- 1998-09-29 CA CA002304973A patent/CA2304973C/en not_active Expired - Fee Related
- 1998-09-29 EP EP98950824A patent/EP1019020A1/en not_active Withdrawn
- 1998-09-29 ME MEP-41/08A patent/MEP4108A/en unknown
- 1998-09-29 EP EP98950826A patent/EP1019021B2/en not_active Expired - Lifetime
- 1998-09-29 ES ES98953220T patent/ES2195408T5/en not_active Expired - Lifetime
- 1998-09-29 WO PCT/US1998/020613 patent/WO1999016421A1/en active IP Right Grant
-
2000
- 2000-03-16 IL IL135126A patent/IL135126A/en not_active IP Right Cessation
- 2000-03-17 BG BG104253A patent/BG64816B1/en unknown
- 2000-03-24 IS IS5415A patent/IS2154B/en unknown
- 2000-03-28 NO NO20001618A patent/NO340149B1/en not_active IP Right Cessation
- 2000-03-28 HR HR20000175A patent/HRP20000175B1/en not_active IP Right Cessation
-
2001
- 2001-01-19 HK HK01100524A patent/HK1031680A1/en not_active IP Right Cessation
-
2009
- 2009-12-01 JP JP2009274003A patent/JP2010047615A/en not_active Withdrawn
-
2011
- 2011-03-16 JP JP2011058608A patent/JP5739197B2/en not_active Expired - Lifetime
-
2013
- 2013-07-08 JP JP2013142326A patent/JP6100114B2/en not_active Expired - Lifetime
- 2013-07-11 JP JP2013145351A patent/JP2013216688A/en not_active Withdrawn
-
2014
- 2014-06-24 JP JP2014128936A patent/JP6078498B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2304819A1 (en) | Perforated microparticles and methods of use | |
CA2346791A1 (en) | Flow resistance modulated aerosolized active agent delivery | |
CA2322045A1 (en) | Aerosolized active agent delivery | |
SI1158958T1 (en) | Improved powdery pharmaceutical compositions for inhalation | |
WO2001005429A3 (en) | Powder particles with smooth surface for use in inhalation therapy | |
CA2412561A1 (en) | Highly efficient delivery of a large therapeutic mass aerosol | |
ATE382386T1 (en) | MULTIDOSIS DRY POWDER INHALER WITH POWDER RESERVOIR | |
GB9606677D0 (en) | Process and device | |
CA2445516A1 (en) | Metered dose delivery device for liquid and powder agents | |
CA2369722A1 (en) | Powder inhaler for combined medicament | |
AP1861A (en) | Dry powder inhalation system for transpulmonary administration | |
MY129384A (en) | "pharmaceutical formulations for dry powder inhalers in the form of hard-pellets" | |
EP1181944A3 (en) | Dynamic particle size control for aerosolized drug delivery | |
NZ332669A (en) | A dry power inhalation system which is flow rate independent | |
IS1768B (en) | Inhalant pharmaceutical composition containing insulin | |
JO2430B1 (en) | Pharmaceuticall Formulations for Dry Powder Inhalers in the form of Hard- Pellets | |
WO2001036015A3 (en) | Powder inhaler | |
HK1025270A1 (en) | Disposable inhaler | |
CA2369726A1 (en) | Powder inhaler for combined medicament | |
WO2006008517A3 (en) | Use of dry powder compositions for pulmonary delivery | |
AU2001252306A1 (en) | Powder inhaler | |
WO2002043693A3 (en) | Pharmaceutical compositions for inhalation | |
WO2004017942A8 (en) | Inhalation compositions with high drug ratios | |
MY136601A (en) | Dry powder inhalation system for transpulmonary administration, method of manufacturing a dry powdered preparation, and use of a freeze dried composition | |
ME00003B (en) | Perforated microparticles and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20181001 |